We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+0.01%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.47B
AUM Growth
+$68.2M
Cap. Flow
+$104M
Cap. Flow %
7.05%
Top 10 Hldgs %
50.84%
Holding
50
New
15
Increased
9
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$85.6M
2
NUVA
NuVasive, Inc.
NUVA
+$51.4M
3
CI icon
Cigna
CI
+$41.4M
4
XRAY icon
Dentsply Sirona
XRAY
+$25.9M
5
PRGO icon
Perrigo
PRGO
+$23.4M

Top Sells

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$55.7M
2
ABBV icon
AbbVie
ABBV
+$43.9M
3
BRKR icon
Bruker
BRKR
+$36.9M
4
CNMD icon
CONMED
CNMD
+$33.9M
5
MASI
Masimo
MASI
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 66.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$41.2B
$103M 7.04%
1,750,000
+100,000
+6% +$6.17M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
$103M 7.01%
500,000
-500,000
-50% -$105M
AZN icon
3
AstraZeneca
AZN
$266B
$79.6M 5.42%
+1,250,000
New +$85.6M
XLV icon
4
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
$74.4M 5.06%
+1,000,000
New +$74.1M
MASI
5
DELISTED
Masimo
MASI
$73.6M 5.01%
1,900,000
-800,000
-30% -$28.7M
MDCO
6
DELISTED
Medicines Co
MDCO
$71.5M 4.87%
2,500,000
– –
ESRX
7
DELISTED
Express Scripts Holding Company
ESRX
$66.7M 4.54%
750,000
+50,000
+7% +$4.37M
CYBX
8
DELISTED
CYBERONICS INC
CYBX
$59.5M 4.05%
1,000,000
+250,000
+33% +$15.7M
GHDX
9
DELISTED
Genomic Health, Inc.
GHDX
$58.4M 3.97%
2,100,000
– –
SEM
10
DELISTED
Select Medical
SEM
$56.7M 3.86%
6,496,000
+928,000
+17% +$7.79M
UAM
11
DELISTED
Universal American Corp
UAM
$53M 3.61%
5,234,898
– –
NUVA
12
DELISTED
NuVasive, Inc.
NUVA
$52.1M 3.55%
+1,100,000
New +$51.4M
OFIX icon
13
Orthofix Medical
OFIX
$477M
$49.7M 3.38%
1,500,000
– –
JNJ icon
14
CALL
Johnson & Johnson
JNJ
$617B
$48.7M 3.32%
+500,000
New +$50.1M
CI icon
15
Cigna
CI
$76.1B
$48.6M 3.31%
+300,000
New +$41.4M
LH icon
16
Labcorp
LH
$25.9B
$48.5M 3.3%
465,600
– –
ARIA
17
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$47.6M 3.24%
5,750,000
-1,250,000
-18% -$11.1M
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
$34.8M 2.37%
750,000
– –
SQNM
19
DELISTED
SEQUENOM INC NEW
SQNM
$27.4M 1.86%
9,000,000
– –
XRAY icon
20
Dentsply Sirona
XRAY
$2.75B
$25.8M 1.75%
+500,000
New +$25.9M
AMRN
21
Amarin Corp
AMRN
$298M
$24.6M 1.67%
500,000
-100,000
-17% -$4.5M
PRGO icon
22
Perrigo
PRGO
$1.43B
$22.7M 1.54%
+122,748
New +$23.4M
KND
23
DELISTED
Kindred Healthcare
KND
$22.3M 1.52%
1,100,000
-400,000
-27% -$9.16M
CCRN
24
DELISTED
Cross Country Healthcare
CCRN
$18.9M 1.29%
1,493,765
+71,200
+5% +$807K
NKTR icon
25
Nektar Therapeutics
NKTR
$2.41B
$18.8M 1.28%
+100,000
New +$17.2M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Camber Capital Management held 50 positions worth $1.47B, up 4.9% from $1.4B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Camber Capital Management deployed $104M of net new capital in Q2 2015, opening 15 new positions and adding to 9 existing holdings. Its largest new stake was AstraZeneca: 1,250,000 shares worth $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 62% a quarter earlier.

On the sell side, the largest reduction was Masimo, an estimated $28.7M trimmed.

  • Camber Capital Management's largest Q2 2015 buy was AstraZeneca: 1,250,000 shares worth $79.6M.
  • Camber Capital Management added most to CYBERONICS INC in Q2 2015, an estimated $15.7M increase.
  • Camber Capital Management's biggest Q2 2015 reduction was Masimo, cutting an estimated $28.7M.
  • Camber Capital Management fully exited AMAG Pharmaceuticals in Q2 2015, selling an estimated $55.7M.
  • Camber Capital Management's ten largest holdings make up 51% of its $1.47B portfolio in Q2 2015.
  • Camber Capital Management opened 15 new positions and closed 8 in Q2 2015.
  • Camber Capital Management's portfolio value rose 4.9% quarter-over-quarter to $1.47B.

Based on Camber Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.